Digital health coaching platform Pack Health has announced a partnership with diabetes data management provider Glooko to integrate blood glucose monitoring. The integration will augment diabetes health coaching and care coordination services with remote real-time data for blood glucose control.Pack Health & Glooko Integration DetailsIntegrating data from Glooko's diabetes management app into Pack Health's coaching platform for chronic care management and monitoring will enable Health
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
Livongo to Offer 10.7 Million Shares in IPO, Priced Between $20 & $23 Per Share
Livongo Health, Inc., today announced it plans to offer 10,700,000 shares of its common stock to the public with the price expected to be between $20.00 and $23.00 per share. Livongo has applied to list its common stock on the Nasdaq Global Select Market under the symbol “LVGO.” Livongo also intends to grant the underwriters a 30-day option to purchase up to an additional 1,605,000 shares of common stock from Livongo.Livongo offers an integrated suite of solutions to promote sustainable health
Read More
Pilot Study: Lark Health’s AI-Driven Diabetes Management Program Decreased A1c by 1.1 Points
Lark Health, a chronic disease prevention and management platform has released initial results from a pilot study of its Diabetes Management Program (Lark DMP). After an average of four months, the Lark DMP users reported a significant reduction in A1c levels of 1.1 points, from 8.5 to 7.4 percent.Lark Diabetes Management Program OverviewThe Lark DMP, which uses conversational artificial intelligence (AI), rather than live telephonic nurses, was developed with the collaboration of industry and
Read More
Digital Health Company Livongo Files for $100M IPO
Livongo Health, Inc., today announced that it has publicly filed a registration statement for a proposed initial public offering (IPO) of its common stock, according to the U.S. Securities and Exchange Commission (SEC) filing. Livongo has applied to list its common stock on the Nasdaq Global Select Market under the ticker symbol "LVGO."Livongo Growth MetricsFounded in 2014, Livongo offers an integrated suite of solutions to promote sustainable health behavior change based on easy, real-time data
Read More
Apple to Sell One Drop’s Blood Glucose Monitors in Select Retail Stores
One Drop, a digital blood glucose monitoring kit for diabetes management will now be available in select retail Apple stores, CNBC reports. Currently sold online in the Apple Store for $69.95, the digital diabetes kit includes a Bluetooth glucose meter, test strips, lancets (optional), and one year of free coaching from a certified diabetes coach.One Drop Blood Glucose MonitorOne Drop’s blood glucose meter ensures clinically proven accurate, reliable results in just five seconds. The meter then
Read More
Livongo Announces Bi-directional Integration with Apple, Fitbit, Samsung Smartwatches
Livongo, a leading Applied Health Signals company empowering people with chronic conditions, today announced the launch of a bi-directional integration with the top smartwatches in the market, including leading models from Apple, Fitbit, and Samsung. Livongo Members can now connect their smartwatches to the Livongo mobile app to receive real-time Livongo notifications on the surface of their choice enabling Livongo to provide more timely and relevant information to Members and their care
Read More
Research: Livongo for Diabetes Program Improved Diabetes Distress Levels
Livongo, an Applied Health Signals company empowering people with chronic conditions to live better and healthier lives, today announced the findings of a study conducted in collaboration with Eli Lilly and Company that demonstrated 94 percent of Livongo program Members who participated in a program survey achieved improved Diabetes Empowerment Scale-Short Form (DES-SF) or Diabetes Distress Scale 2 (DDS2) in year one. The research findings were presented on June 8, 2019, at the American Diabetes
Read More
Companion Medical Integrates Smart Insulin Pen with Rimidi Diabetes Management App
Rimidi and Companion Medical announced a first-of-its-kind partnership to enhance data visualization for clinicians treating high-risk patients with diabetes who are on insulin therapy. The collaboration integrates Companion Medical’s connected device, InPen™, the first and only FDA-cleared, smart insulin pen paired with an integrated diabetes management app, into Rimidi’s platform by pushing insulin dosing data from the InPen through the cloud.Integration BenefitsThis partnership reduces the
Read More
Glooko Integrates Insulin Data with Companion Medical’s Smart Insulin Injection Pen
Glooko and Companion Medical have announced an integrated data partnership agreement that will enable insulin data from users of the InPen Smart Insulin Injection Pen to be integrated into the Glooko Enterprise diabetes data management system and Glooko Mobile App.
Impact of Integration
The announcement of this integration is significant because InPen is the first “smart” insulin pen to introduce its data integration and compatibility with the Glooko platform
Read More
Glooko Appoints Dr. Mark Clements as Chief Medical Officer
Glooko, a provider of diabetes data management solutions, today announced the appointment of Mark Clements, MD, Ph.D., CPI, FAAP, as Chief Medical Officer. Dr. Clements joins the senior management team of Glooko having served on its medical advisory board since it was formed in 2015 to provide expertise to the organization in the areas of clinical studies and diabetes analytics.
Dr. Clements comes to Glooko from the University of Missouri-Kansas City School of Medicine, where he is Associate
Read More
